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Objective: Infrainguinal angioplasty provides a minimally invasive alternative to bypass surgery in patients with critical
ischemia. This study aimed to determine the 2-year patency, limb salvage, and survival rates in patients who underwent
infrainguinal angioplasty in a unit where angioplasty is used preferentially whenever possible for critical ischemia.
Methods: A total of 333 consecutive patients who presented with rest pain, tissue loss, or both and who underwent an
infrainguinal intervention in the 4-year period between January 1998 and January 2002 were divided into femoropop-
liteal and femorodistal groups. The TransAtlantic Inter-Society Consensus angiogram scoring system was used to classify
the lesions. Angioplasty was the preferred procedure in all patients for whom a stump or portion of a superficial femoral
artery was patent. Exclusion criteria included the concomitant or sequential treatment of iliac lesions. Patients were
followed up after surgery with ankle-brachial indices and duplex ultrasonography.
Results: A total of 180 patients underwent 198 angioplasties. Primary cumulative patency, limb salvage, and survival for
femoropopliteal angioplasty (n  166) at 2 years were 75%, 90%, and 88%, respectively, and 60%, 76%, and 82% for
infrapopliteal angioplasty (n  32). At 30 days, mortality was 2.7%, and the complication rate was 8.3%. There was a
restenosis rate (>50%) of 68% and 65% at 2 years for the femoropopliteal and infrapopliteal angioplasty groups,
respectively. Seven patients required repeat angioplasty of the same site, 30 underwent subsequent bypass, and 16 of 43
occluded limbs were amputated. A total of 153 comparative control patients underwent 162 bypass procedures during
the same period. Primary cumulative patency, limb salvage, and survival for femoropopliteal bypass (n  80) at 2 years
were 69%, 87%, and 76%, respectively, and were 53%, 57%, and 64% for infrapopliteal bypass (n  82). The 30-day
mortality for bypass was 5.2%, the complication rate was 35%, and 31 limbs were amputated.
Conclusions: The results of this study on the intermediate-term outcome of angioplasty suggest that angioplasty, when
used preferentially for critical ischemia, in anatomically suitable patients provides very acceptable limb salvage and
survival despite a relatively high restenosis rate. ( J Vasc Surg 2006;43:504-12.)Since its introduction in 1964, angioplasty has been
recognized as a useful technique in the management of
chronic limb ischemia.1 Most of the initial studies per-
formed to determine the role of angioplasty consisted of
patients who were unsuitable for surgical bypass, and the
only endovascular technique used was transluminal angio-
plasty. Technological advances and the introduction of
subintimal angioplasty have increased the role of angio-
plasty in the management of critical limb ischemia.2,3
Blair et al4 reported a 2-year patency of 18% for infrain-
guinal angioplasty and concluded that the patency for
bypass was significantly better. In contrast, London et al5
showed a 2-year patency, limb salvage, and survival rate for
angioplasty of 77%, 89%, and 76%, respectively, with low
associated morbidity. The same group recently reported a
3-year limb salvage rate of 94% in 67 consecutive patients
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504who underwent subintimal angioplasty of isolated infra-
genicular vessels.3 Similarly, Boyer et al6 reported primary
patency, limb salvage, and survival rates for angioplasty of
81%, 87%, and 75%, respectively, at 21 months.
It is unclear whether the preferential use of angioplasty
for critical ischemia leads to outcomes comparable to those
with bypass procedures in individual units. The aim of this
study was to determine the 2-year patency, limb salvage,
and survival rates of patients with infrainguinal critical limb
ischemia treated by angioplasty or bypass over a 4-year
period.
PATIENTS AND METHODS
All patients who presented to St James’s Hospital with
rest pain, tissue loss, or both between January 1998 and
January 2002 and who had an infrainguinal operative in-
tervention were identified. Patients who were treated non-
operatively or who underwent a prior or concomitant aor-
toiliac bypass or endovascular procedure were excluded.
Angioplasty or bypass was performed as the initial vascular
procedure on 333 patients. Patients were analyzed on an
intention-to-treat basis. There were 180 patients (198
limbs) in the angioplasty group. During the same period,
153 patients (162 limbs) underwent a primary infrainguinal
bypass procedure. Angioplasty was the preferred procedure
in all patients for whom a stump or portion of superficial
femoral artery was patent. Bypass was the preferred proce-
dure in patients with either a flush occlusion of their super-
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angioplasty. Other factors that favored bypass were renal
impairment and allergy to contrast media.
All patients underwent physical examination, segmen-
tal pressuremeasurement (ankle-brachial index [ABI]), and
preoperative duplex scanning. Preoperative or intraopera-
tive angiograms were used to classify lesions according to
the TransAtlantic Inter-Society Consensus (TASC) angio-
gram scoring system.7 We divided the available data into
two groups to compare the results at the same anatomical
level: a femoropopliteal (FP) group and an infrapopliteal
(IP) group. All procedures were performed by a vascular
surgeon or a trainee under supervision in the operating
room or endovascular suite. Angioplasty was performed
with the patient under local anesthesia in 130 (66%) pro-
cedures, general anesthesia in 42 (21%), and regional anes-
thesia in 26 (13%). Access was obtained through a 6F or 7F
sheath via an ipsilateral antegrade or contralateral retro-
grade approach. Digital subtraction angiography was per-
formed to define the lesion and runoff vessels. Patients
received 3000 to 5000 IU of unfractionated heparin during
surgery before the lesion was crossed with a 0.89- or
0.46-mm hydrophilic coated guidewire and a 5F straight
(Van Andel) or angled (Pier) catheter. Transluminal angio-
plasty was performed for lesions that were accessible with
the guidewire, and subintimal angioplasty was used for
cases in which a stump or portion of a superficial femoral
artery was patent. Five- or 6-mm balloons of varied lengths
(2-10 cm) were used for FP lesions (inflated to 8-12 atm),
whereas 3- or 4-mm balloons were used for tibial lesions
(inflated to 10-16 atm). The decision as to the extent of
disease to treat was difficult to define because it depended
on local factors, such as vessel calcification, ease of access,
and trackability, as well as patient factors, such as type of
anesthesia, patient discomfort, and renal impairment. The
success of the first level treated in terms of improved flow
determined the need for treatment of distal lesions. Intralu-
minal self-expanding stents were used only in cases of
failure to achieve patency because of an intimal flap. They
were not used routinely in vessels with residual stenosis and
were never used in tibial arteries. Postoperative heparin at
500 IU/hwas continued for 24 hours. All patients received
a statin and antiplatelet therapy consisting of aspirin 75 mg
for life and clopidogrel 75 mg for 6 weeks after surgery.
They occasionally received warfarin, at the discretion of the
surgeon.
Patients underwent ABI measurement 24 hours after
surgery and were reviewed at 6 weeks and 6, 12, 18, and 24
months with examination, duplex scanning, and ABIs. The
success rate was determined on the basis of clinical, hemo-
dynamic, and anatomic factors. Clinical success required
symptomatic improvement of patients or healing of lesions
compared with their preoperative assessment. Hemody-
namic success was defined as an improvement in ABI of
greater than 0.15. Preprocedure and postprocedure ABI
data were available for 90% of the angioplasty group and for
86% of the bypass group. Toe pressure data from patients
considered to have falsely increased ABI due to incompress-ible vessels were used for diagnosing critical ischemia but
were not included in the analysis of ABI. For angioplasty,
anatomic success was defined as a residual luminal stenosis
of less than 30%. Late failure was determined by clinical
assessment and ABI or duplex confirmation of occlusion.
Details of each patient and procedure were entered
prospectively at the time of intervention into a computer-
ized database (Vascubase, Consensus Medical Systems Inc,
Richmond, British Columbia), and follow-up data were
collected by an independent database manager. Categorical
frequency data were analyzed by the Yates 2 test or Fisher
exact test: a two-sided significance level of P  .05 was
considered significant for the purposes of this study. The
Kramer V value was used to test for strength of association
between variables for which significant differences were
found between groups. The paired t test was used for paired
data (preoperative and postoperative ABIs). We modified
the TASC scoring system to categorize individual limbs on
the basis of the worst TASC lesions present rather than the
worst treated lesions. This method was used to compare the
treatment of limbs with similar multiple lesions, not all of
which may have been treated by angioplasty. Life-table
estimates for primary patency, limb salvage, and survival
were compared by using the log-rank test in accordance
with reporting standards,8 and standard errors (and 95%
confidence intervals) were calculated by using the method
described by Peto et al.9
RESULTS
Between January 1998 and January 2002, 180 patients
(198 limbs) were treated with percutaneous transluminal or
subintimal angioplasty. There were 97men and 83 women,
and the mean age was 68 years (range 45-91 years). Risk
factors for atherosclerosis, comorbidity, and American So-
ciety of Anesthesiologists grade are listed in Table I. The
indications for treatment in the angioplasty group were rest
pain in 39% and tissue loss in 61%.
The proportion of limbs in each TASC group are
Table I. Patient characteristics (n  333)
Variable Angioplasty Bypass P value
Smoking 102 (57%) 90 (59%) .78
Hypertension 80 (44%) 60 (39%) .39
Hyperlipidemia 32 (18%) 35 (23%) .31
Diabetes mellitus 52 (29%) 47 (31%) .81
Cardiac 61 (34%) 54 (35%) .89
COPD 23 (13%) 43 (28%) .0008 (.1916)
Renal impairment 6 (3%) 5 (3%) .86*
ASA class
I 32 (18%) 19 (12%) .23
II 91 (51%) 100 (65%) .009 (.1492)
III 51 (28%) 32 (22%) .152
IV 6 (3%) 2 (1%) .40*
COPD, Chronic obstructive pulmonary disease; ASA, American Society of
Anesthesiologists.
P values represent analysis by Yates 2 or *Fisher exact tests. The Kramer V
test for strength of association is given in parentheses after significant P
values.detailed in Table II. When we combined the TASC lesions
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TASC lesions present, we found that in the FP angioplasty
group, only 7 limbs were type A, 20 limbs were type B and
type C, and 119 limbs were type D. In the IP angioplasty
group, 1 limb was type C, and 31 limbs were type D. No
limb in the IP angioplasty group had an isolated type A or
type B lesion (Table III).
The common or superficial femoral artery was the
primary site for angioplasty in 173 limbs (87%). The pop-
liteal artery was the primary site in 17 (9%) limbs, and a
tibial vessel was the primary site in 8 limbs (4%). We also
looked at levels of disease treated: 89 limbs had 1 level, 77
limbs had 2 levels, and 32 had 3 levels of disease treated.
Forty-nine (24%) limbs had poor distal runoff (0 or 1 tibial
vessel), and 149 (76%) had good distal runoff (2 or 3 tibial
vessels), not necessarily in continuity with the foot.
The median length of the lesion treated was 5 cm
(range, 2-25 cm). A total of 102 limbs were treated by
subintimal angioplasty, and 58 lesions measured 10 cm or
more. Ninety-six limbs were treated by transluminal angio-
plasty. Only three self-expanding stents were placed: two
superficial femoral and one popliteal.
The technical success rate was 92% (183/198). Of the
15 patients with immediate treatment failure, 5 underwent
thrombectomy or bypass within 24 hours.
FP group. A total of 166 limbs in the FP group were
treated by angioplasty. ABI increased from 0.59  0.16
before surgery to 0.87  0.24 after surgery (P  .05;
Table II. Conventional TASC scores for lesions treated
by angioplasty and bypass, compared with modified
TASC scores, where the most severe lesion on the limb











Type A 48 7* 0 0
Type B 46 20* 0 0
Type C 70 21* 50 34
Type D 34 150* 112 128
TASC, TransAtlantic Inter-Society Consensus.
*P .001 compared with the TASC score by the Yates 2 test. Kramer V test
 0.62 for the 4  2 table of cross-categorized angioplasty data, thus
indicating strongly that treatment of a TASC lesion type did not correlate
with the presence of a TASC lesion type.
Table III. Combined worst TASC scores for each limb
Variable
Femoropopliteal Infrapopliteal
Angioplasty Bypass Angioplasty Bypass
Type A 7 0 0 0
Type B 20 0 0 0
Type C 20 24 1 10
Type D 119 56 31 72
TASC, TransAtlantic Inter-Society Consensus.Table IV).The cumulative primary patency rates (as defined by
freedom from occlusion or reintervention) for the FP an-
gioplasty group at 1, 6, 12, and 24 months were 91%, 86%,
79%, and 75%, respectively. The freedom from 50% or
greater restenosis rates are shown on the same graph for
comparison (Fig 1). Cumulative limb salvage for FP angio-
plasty at 1, 6, 12, and 24 months was 98%, 97%, 94%, and
90%, respectively (Fig 1). The cumulative survival rate for
the FP angioplasty group at 2 years was 88% (Fig 1).
IP group. Thirty-two limbs were treated with angio-
plasty in the IP group. ABI increased from 0.56  0.13
before surgery to 0.84  0.23 after surgery (P  .05;
Table IV).
The cumulative primary patency for IP angioplasty at 1,
6, 12, and 24 months was 86%, 75%, 67%, and 60%,
respectively (Fig 2). Cumulative limb salvage for the IP
angioplasty group at 1, 6, 12, and 24 months was 90%,
90%, 82%, and 76%, respectively (Fig 2). The survival rate
for IP angioplasty at 2 years was 82% (Fig 2).
Outcomes according to TASC group. The cumula-
tive primary patency at 2 years for TASC lesions A, B, C,
and D was 73%, 62%, 65%, and 55%, respectively (Fig 3).
Secondary patency at 2 years was 84%, 74%, 72%, and 72%
(Fig 4, online only). The 2-year limb salvage and survival
rates were 94%, 90%, 87%, and 89% (Fig 5, online only) and
87%, 88%, 93%, and 96%, respectively (Fig 6, online only).
Morbidity and secondary procedures. There were
five (2.7%) perioperative deaths within 30 days in the angio-
plasty group (2 cardiac, 1 pulmonary, and 2 multiple organ
failure), and 11 patients died during follow-up. The 30-day
complication rate was 8.3%. Morbidity consisted of eight
(4%) access site hematomas, two thromboses, one cardiac
complication, six pulmonary complications, and two renal
failures.
Forty-seven patients (26%) underwent 53 subsequent
procedures, which included repeat angioplasty of the same
site (n  7), bypass (n  30), and major amputation (n 
16; 8%). Eight bypasses were performed within the first
month, 21 by 6 months, 26 by 1 year, and 30 by 2 years.
Before the major amputations, four patients had redo an-
gioplasty, and eight patients had an attempted bypass. The
2-year patency, limb salvage, and survival of patients who
underwent bypass after failed angioplasty were 52%, 71%
and 78%, respectively. A total of 66% of amputations after
failed angioplasty were below the knee.
Comparison with bypass procedures. A total of 153
patients underwent 162 bypass procedures during the same
time period. Patient characteristics and indications are
shown in Tables I and II. There were a higher proportion of
patients with chronic obstructive pulmonary disease in the
bypass group when compared with the angioplasty group.
The Kramer V value was low, however, thus indicating a
weak association between variables. Bypass was more com-
monly performed for rest pain (53%) than for tissue loss
(47%): this differed significantly from the angioplasty
group, in which tissue loss was the indication in 61% (P 
.0097, Yates 2 test). The association was again weak
(Kramer V 0.1419). Patients underwent general anesthe-
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plastied patients, in whom 66% had only local anesthesia. A
total of 46 limbs were classified as TASCC lesions, and 116
limbs were classified as TASC D (Table II). A total of 69
(42%) limbs had poor runoff (0 or 1 tibial vessel), and 93
(57%) had good runoff (2 or 3 tibial vessels). A reversed or
in situ autogenous vein was the conduit of choice in the
bypass group and was used in 70% (114/162) of cases. The
great saphenous vein was used in 92 cases, the arm vein in
21, and the short saphenous vein in 1. Polytetrafluoroeth-
ylene (PTFE) was used in 34 (43%) of 80 limbs in the FP
group (26 above knee and 8 below knee) and 14 (21%) of
82 limbs in the IP group as a result of unsuitability or
unavailability of a vein.
The primary cumulative patency for FP bypass (n 80)
at 1, 6, 12, and 24 months was 96%, 85%, 76%, and 69%;
limb salvage was 98%, 90%, 90%, and 87%; and survival was
Table IV. Hemodynamic success of interventions as indic
Type of bypass
Angioplasty (n  137)
Before surgery After surgery
Femoropopliteal 0.59 (0.16) 0.87 (0.24)
Femorodistal 0.56 (0.13) 0.84 (0.23)
Preoperative ankle-brachial index (ABI) 0.9 was excluded from calcul
preoperative ABI (paired two-tailed t test). P  .05 for differences between
t test).
Fig 1. Two-year limb salvage, survival, primary patenc
angioplasty.97%, 92%, 85%, and 76%, respectively (Fig 7). For IP bypass(n  82), primary patency at 1, 6, 12, and 24 months was
70%, 56%, 53%, and 53%; limb salvage was 79%, 60%, 57%,
and 57%; and survival was 93%, 85%, 76%, and 64%, respec-
tively (Fig 7). When the results of the FP bypass group were
compared with those of the FP angioplasty group, there
was a significant difference in the 2-year cumulative survival
rate (FP bypass group, 76%; FP angioplasty group, 88%;
P .02 by log-rank test) but not in the cumulative patency
(FP bypass group, 69%; FP angioplasty group, 75%; P 
.05) or limb salvage (FP bypass group, 87%; FP angio-
plasty group, 90%; P  .05). Similarly, comparing the IP
groups, there was a significant difference in survival at 1
year (FP bypass group, 76%; FP angioplasty group, 92%)
and 2 years (FP bypass group, 64%; FP angioplasty group,
82%; P  .01, log-rank test). There was also a significant
difference in limb salvage (FP bypass group, 57%; FP an-
gioplasty group, 76%; P .05), but not in primary patency
by changes in ankle-brachial indices (SD)
Bypass surgery (n  130)
value Before surgery After surgery P value
0001 0.52 (0.18) 0.87 (0.22) .0001
0002 0.52 (0.17) 0.84 (0.3) .0001
P values represent tests of differences in postoperative compared with
plasty and bypass both for preoperative and postoperative ABI (two-tailed





angioy, and(P  .05).
Tran
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24 months was similar (86% and 69% vs 93% and 66%,
respectively.) In the femorodistal group, the cumulative
patency at 1 and 24 months for vein grafts was better than
for PTFE (85% and 72% vs 62% and 53%, respectively). The
outcomes according to TASC lesion are shown in Fig 8.
There were 26 cases of early graft thrombosis in the
bypass group. Eleven of these cases had an attempted
thrombectomy or thrombolysis. Only two were successful.
Six of these patients underwent redo bypass operation, and
Fig 2. Two-year limb salvage, survival, primary paten
angioplasty.
Fig 3. Angioplasty primary patency according to18 patients required a major amputation (14 above kneeand 4 below knee). Infection did not play a role in the
amputation rate. Overall, 64 patients underwent 71 sec-
ondary procedures, including graft thrombectomy (n 9),
patchplasty (n  13), graft revision (n  12), below-
knee amputation (n  7), and above-knee amputation
(n  24).
Eight (5.2%) perioperative deaths occurred in the by-
pass group (2 cardiac, 2 pulmonary, 1 renal failure, and 3
multiple organ failure), and 39 patients died during the
follow-up period. The 30-day complication rate was 35%,
d freedom from 50% restenosis rates of infrapopliteal
sAtlantic Inter-Society Consensus (TASC) score.cy, anconsisting of 8 hematomas, 9 wound infections, 4 cardiac
ry pat
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cations, and 26 graft thromboses.
DISCUSSION
A key problem in the comparison of data from bypass
and angioplasty groups in any series is the lack of consensus
between and among surgeons and radiologists with regard
to the choice of intervention for severe limb ischemia.10 It
is somewhat surprising that such an obvious deficiency in
evidence still exists, and the results of the Bypass vs Angio-
plasty for Severe Ischemia of the Leg (BASIL) trial are
awaited with interest.
This series documents all the patients during the study
period who underwent bypass or angioplasty for severe
Fig 7. Two-year limb salvage, survival, and primalimb ischemia secondary to infrainguinal peripheral vasculardisease. The two groups are not comparable because the
authors are biased toward offering angioplasty as first-line
therapy in all anatomically suitable patients. Nevertheless, it
is important to present data on all patients treated in a unit
with such a policy, because a review of angioplasties alone
would leave doubts as to whether the authors were choos-
ing predominantly low-risk patients compared with those
who underwent bypass. The patency and limb salvage rates
of angioplasty in this study compare favorably to our own
and other reported results for bypass surgery.11-13 The
cumulative primary patency rate for the FP angioplasty
group was 75% at 2 years, which was similar to the 69% seen
in the FP bypass group (Figs 1 and 7), thus indicating
respectable durability for angioplasty. The cumulative pri-
ency of femoropopliteal and infrapopliteal bypass.mary patency for IP angioplasty was also not significantly
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2 and 7). The low primary patency rate of the IP bypass
group may reflect the policy of saving bypass for patients
anatomically unsuitable for angioplasty.
Cumulative limb salvage for FP angioplasty was 90% at
2 years, compared with 87% for FP bypass, whereas limb
salvage for IP lesions was 76%, compared with 57% for IP
bypass (P  .05). These results seem to favor angioplasty.
There was a high rate of amputation after failed bypass (32
of 44 occluded grafts; 75%) compared with failed angio-
plasty (16 of 43 occluded limbs; 37%). Surprisingly few
patients required repeat angioplasty of the same site (n 7),
and only 16 limbs were lost. This was despite a restenosis
Fig 8. Bypass primary patency, limb salvage, and surviva
score.rate (50%) of 68% at 2 years for the FP group, perhapsindicating that patency rates may be of less importance
when compared with limb salvage for this group of elderly
patients.14 The fate of patients who underwent bypass after
failed angioplasty was interesting, because the patency,
limb salvage, and survival of 52%, 71%, and 78%, respec-
tively, at 2 years were similar to our results for primary
bypass. This is in contrast to Molloy et al,15 who reported a
high amputation and mortality rate in patients with failed
angioplasty.
There was a survival advantage for angioplasty over
bypass at the 2-year follow-up (95% confidence interval for
absolute survival advantage, 9.6%-22.4%). It is notable that
61% of patients in the angioplasty group had tissue loss,
rding to TransAtlantic Inter-Society Consensus (TASC)l accocompared with 47% in the bypass group. The difference was
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2-year survival rates for IP angioplasty were 92% and 82%,
respectively, compared with 76% and 64% for bypass
(P  .01). This is all the more interesting because one
might intuitively expect that any bias should place unfit
patients with a limited life expectancy into the angioplasty
group, as advocated by some authors.16,17 Our practice has
changed considerably from an earlier reported series,18 in
which angioplasty was reserved in many cases for patients
unfit for bypass surgery, to now performing angioplasty as
the first choice in all anatomically suitable patients with at
least a stump of a superficial femoral artery.
The TASC scoring system was introduced to allow
comparison of lesions treated within and between reported
series. When we categorized individual limbs on the basis of
the worst TASC lesions present rather than the worst
treated lesions, we found very few limbs in the FP group
that had type A or B lesions and no limb in the IP angio-
plasty group that had an isolated type A or B lesion (Tables
II and III). The rationale behind this method is that many
angioplastied limbs had multiple lesions, not all of which
may have been treated by angioplasty. The comparable
number of TASC C and D lesions illustrates the fact that
most patients treated by angioplasty had multilevel occlu-
sive disease, similar to patients treated by bypass. It is
apparent, however, that patients in the angioplasty group
were less likely to have three levels of disease treated than
those in the bypass group.
Baseline ABIs were higher in the angioplasty group
despite similar numbers of diabetics treated. The usefulness
of the hemodynamic data was also limited by the apparent
lack of correlation between clinical success and the magni-
tude of the initial ABI change after angioplasty in many
cases. Patients who underwent angioplasty were also less
likely to have poor runoff than those treated by bypass;
therefore, it is possible that their anatomic suitability for
angioplasty could account for the comparable patency and
limb salvage and better survival rates. Nevertheless, this
does not detract from the fact that all patients treated in
both groups had rest pain or tissue loss and that angioplasty
provided a satisfactory outcome in most patients. Although
previous studies have shown lower perioperative mortality
rates for angioplasty,19,20 our results suggest that long-
term survival may also be better. This is also supported by
the finding that morbidity was higher in the bypass group
(32% vs 8.3%). Furthermore, it cannot be assumed that the
bypass group would have had a less than equal probability
of survival than the angioplasty group to begin with, be-
cause it is also possible that the nature of the intervention
has a profound bearing on the survival outcome. For exam-
ple, an important difference in outcome may be due to the
fact that most angioplasties were performed with the pa-
tient under local anesthesia (71%) as opposed to regional or
general anesthesia. There is little evidence, however, to
support such a view in the absence of randomized data. It is
equally possible that the larger number of amputations that
occurred in the bypass group after occlusion or the higherproportion of patients with chronic obstructive pulmonary
disease may have skewed the survival data.
This study adds to the argument that angioplasty is an
appropriate and effective first-line therapy for critical
ischemia, despite a high restenosis rate, because of the
impressive limb salvage and survival achieved, with minimal
morbidity. We believe that the results of randomized con-
trolled trials comparing angioplasty with bypass will be
helpful in reducing the present level of discordance among
clinicians.
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